Article
Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2015
Bodnar L, Stec R, Cierniak S, Synowiec A, Wcisło G, Jesiotr M, Koktysz R, Kozłowski W, Szczylik C
Abstract excerpt
BACKGROUND: The aim of this study was to search for predictive and prognostic factors in patients with metastatic renal cell carcinoma (mRCC) treated with everolimus among the components of PI3K/AKT/mTOR pathway. PATIENTS AND METHODS: In a prospective, one-arm, phase II study, patients with mRCC received everolimus (10 mg/day) using a 30-day cycle. A prospectively planned evaluation of potential biomarkers of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.